The proof of the pudding is in the eating of it, not in the pudding or its concealed ingredients. Don’t take my word for it. From New York come two cases that were SARS-CoV-2 (COVID-19) antibody negative after developing COVID-19 while on ocrelizumab.
Both cases were aged 39 and 42, within an age range that would be considered immune competent and therefore fully capable of forming an antibody response. First individual had received ocrelizumab for 4 months, the second 9 months prior to COVID-19 infection. Infection was confirmed by nasal swab, and antibody response was checked on two occasions by two different assays; both negative (see Table below).
Of course, an intact B cell pool is not necessarily needed for an adequate immune response to COVID-19, as these two cases prove. Both, recovered following infection. However, the lack of antibody response has obvious implications of vaccine response. This applies not only to COVID-19, but to the flu vaccines, pneumococcal vaccine, chicken pox vaccine, yellow fever vaccine…
Mult Scler Relat Disord. 2020 Jun 26;44:102341.
Negative SARS-CoV-2 Antibody Testing Following COVID-19 Infection in Two MS Patients Treated With Ocrelizumab
Background: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.
Methods: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology.
Results: A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection.
Conclusions: Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production.